NCT07519486 2026-04-15
INS-ESCC-CT
Sichuan University
Phase 2 Recruiting
Clinical Trials
17 trialsNCT06281405 2026-04-03
TORCH-iTNT
Fudan University
Phase 2 Recruiting
NCT07468630 2026-03-12
TRIUNITE-08
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Recruiting
NCT03313804 2026-03-11
Priming Immunotherapy in Advanced Disease With Radiation
University of Kentucky
Phase 2 Completed
NCT06647680 2026-03-06
Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）
The Affiliated Hospital of Qingdao University
Phase 2 Recruiting
NCT07110103 2026-02-27
JACKPOT38
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT04093323 2026-02-25
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Roswell Park Cancer Institute
Phase 2 Terminated
NCT06802757 2026-02-25
PRISM-TNBC
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT07432568 2026-02-25
A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07417501 2026-02-18
Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification
Tongji Hospital
Phase 2 Not yet recruiting
NCT07405086 2026-02-12
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
OHSU Knight Cancer Institute
Phase 2 Not yet recruiting
NCT06610734 2026-02-09
SKY
Sichuan University
Phase 2 Recruiting
NCT07385989 2026-02-04
Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT05621707 2026-02-02
RICE
Shanghai Chest Hospital
Phase 2 Active not recruiting
NCT05166239 2026-01-23
HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT
Peking University
Phase 2 Completed
NCT07364305 2026-01-23
Lalo
Eastern Hepatobiliary Surgery Hospital
Phase 2 Recruiting
NCT07077512 2026-01-21
Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma
Sun Yat-sen University
Phase 2 Recruiting